SHENZHEN, China, April 13 /PRNewswire-FirstCall/ - Hard to Treat
Diseases (HTDS; http://www.htdsmedical.com/) announces that the
company management is proceeding with the company Share Buyback
Program as per the news of April 1
2010 in an effort to raise the value of the company security.
HTDS management plans to continue with the Program, using
financing from sales of some of the company disposable assets. HTDS
management is of opinion that this financing should be sufficient
to raise the price of the security to true worth of HTDS and
satisfy all shareholders and investors.
HTDS' management will advise the public on all new developments
regarding the share reduction program and all other news related to
the HTDS security.
HTDS CEO Terry Yuan said "It is
my understanding that the HTDS team of Slavica Bio Chem and Collagena Skin Care did a
wonderful job at the Business Expo and Shareholders Conference.
Unfortunately, I was unable to attend to meet and greet many HTDS
shareholders that came by the HTDS booth. A soon to be contract
announcement will explain why I needed to focus all my attention on
bringing that contract to a fruition. It is my understanding that a
group from USA will be visiting
Slavica Bio Chem in Serbia for
discussions and cooperation's on some of the projects that division
is working on at the end of April. The USA group is showing particular interest in
the Slavica rejuvenated medical project (see Filing Nov 24)
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=26604
and other medical work the team is engaged in. HTDS will report
back shortly after the conclusion of the USA group due diligence is completed, and we
as a company will report back to our followers the significant and
positive outcome this will have on the entire HTDS
organization."
The company reminds its shareholders and followers to monitor
our IR company web site section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate
updates.
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful
that short sellers, the company competitors and stock bashers stalk
small cap Pink Sheets listed companies with hidden agendas. Visit
http://www.stockbasher.com/ and find out what criminal and civil
actions the US authorities are taking against web sites like
investorshub.com and other posters, and the remedies available to
you as an individual investor.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be,"
"expects," "may affect," "believed," "estimate," "project," and
similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
